Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Acidosis, Respiratory : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Alkalosis, Metabolic

Alveolar Proteinosis

Asphyxiating Thoracic Dystrophy (Jeune Syndrome)

Aspiration Syndromes

Asthma

Atelectasis, Pulmonary

Bronchiectasis

Bronchiolitis

Bronchitis, Acute and Chronic

Bronchopulmonary Dysplasia

Congenital Diaphragmatic Hernia

Congenital Stridor

Croup

Cystic Adenomatoid Malformation

Cystic Fibrosis

Empyema

Goodpasture Syndrome

Hantavirus Pulmonary Syndrome

Head Trauma

Hemosiderosis

Hemothorax

Histoplasmosis

Human Immunodeficiency Virus Infection

Mycoplasma Infections

Near Drowning

Neonatal Resuscitation

Respiratory Distress Syndrome




Patient Education
Click here for patient education.



Author: Margaret A Priestley, MD, Assistant Professor of Anesthesia and Pediatrics, Department of Anesthesiology and Critical Care Medicine, University of Pennsylvania; Associate Director of Trauma, The Children's Hospital of Philadelphia

Margaret A Priestley is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, and Society of Critical Care Medicine

Coauthor(s): Ronald Litman, DO, Department of Anesthesiology, Associate Professor, The Children's Hospital of Philadelphia

Editors: G Patricia Cantwell, MD, Associate Clinical Professor, Department of Pediatrics, University of Miami; Director of Pediatric Critical Care Medicine, Miller School of Medicine, Jackson Children's Hospital; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Barry J Evans, MD, Assistant Professor of Pediatrics, Temple University Medical School; Director of Pediatric Critical Care and Pulmonology, Associate Chair for Pediatric Education, Temple University Children's Medical Center; Mary E Cataletto, MD, Associate Director, Division of Pediatric Pulmonology, Winthrop University Hospital; Associate Professor, Department of Clinical Pediatrics, State University of New York at Stony Brook; Timothy E Corden, MD, Associate Professor of Pediatrics, Co-Director, Policy Core, Injury Research Center, Medical College of Wisconsin; Associate Director, PICU, Children's Hospital of Wisconsin

Author and Editor Disclosure

Synonyms and related keywords: respiratory acidosis, carbon dioxide acidosis, CO2 acidosis, acute respiratory acidosis, chronic respiratory acidosis, hypercapnia, hypercarbia, supercarbia, acidemia, blood pH, acid-base balance, pCO2, minute ventilation, bicarbonate, hypercapnic acidosis, arterial partial pressure of carbon dioxide, hypoxemia, PaCO2, depressed central respiratory drive, acute paralysis of the respiratory muscles, acute parenchymal lung and airway diseases, increased dead space, wasted ventilation, scoliosis, pulmonary vasoconstriction, supraventricular arrhythmias, hypoplastic left heart syndrome, hypercapnic encephalopathy, myasthenia gravis, bronchopulmonary dysplasia, asthma, emphysema, encephalitis, meningitis

Background

Respiratory acidosis occurs when the arterial partial pressure of carbon dioxide (PaCO2) is elevated above the normal range (>44 mm Hg) leading to a blood pH less than 7.35.1 Respiratory acidosis is not a specific disease. Instead, it is an abnormality that results from an imbalance between carbon dioxide (CO2) production by the body and excretion by the lungs, providing adequate minute ventilation. A deficiency of minute ventilation can occur anywhere along the continuum of the respiratory system, from central initiation of ventilation to appropriate gas exchange at the capillary alveolar interface.

Respiratory acidosis may result from an acute or chronic process. Acute respiratory acidosis can be life threatening when a sudden and sharp increase in PaCO2 is associated with severe hypoxemia and acidemia (see Equation 2). In contrast, chronic respiratory acidosis (>24 h) is characterized by a gradual and sustained increase in PaCO2.

By definition, the diagnosis of respiratory acidosis requires measurement of the arterial PaCO2 and pH. When the diagnosis is made, the cause should be thoroughly investigated.

Pathophysiology

PaCO2 is directly proportional to CO2 production and inversely proportional to alveolar ventilation. Alveolar ventilation is responsible for CO2 elimination and is calculated when the respiratory frequency is multiplied by the difference between the tidal volume and the physiologic dead space. Respiratory acidosis results primarily when alveolar ventilation is decreased or if CO2 production is increased.

Many clinical scenarios contribute to inadequate removal of CO2 from the blood. A few examples include depressed central respiratory drive, acute paralysis of the respiratory muscles, acute parenchymal lung and airway diseases, and increased dead space or wasted ventilation. If breathing ceases, arterial CO2 increases further at a rate of 3-6 mm Hg/min. In other cases, hypercarbia gradually develops as it does in a progressive neuromuscular disease, in worsening scoliosis leading to restrictive lung disease, or in chronic pulmonary diseases. In this scenario, persistently elevated PaCO2 leads to effective compensatory mechanisms.

In rare instances, increased CO2 production can exceed the patient's ability to compensate, leading to a respiratory acidosis. This situation occurs during hypermetabolic states, such as extensive burn injury, malignant hyperthermia, or fever when the patient is unable to increase minute ventilation. When PaCO2 accumulates acutely, other organ systems are affected.

General physiologic and metabolic effects

CO2 is carried in the blood in 3 forms: dissolved gas, bicarbonate, and protein bound. It diffuses freely across cell membranes, and this diffusion allows for its efficient transport from peripheral tissues to the lungs for excretion. When hypercapnia is present, this same property causes excess CO2 to shift intracellularly and decrease intracellular pH. CO2 normally combines with water (H2O) to form carbonic acid (H2CO3), which then dissociates to release hydrogen ion [H+] and bicarbonate (HCO3-) (Equation 1). When a respiratory acidosis is present, excess CO2 increases H2CO3 formation, shifting the equilibrium of the equation toward the accumulation of hydrogen ions.

Equation 1: CO2 + H2 H2 CO3  H+ + HCO3-

The body has several compensatory systems to minimize the decrease in pH. Intracellular proteins and inorganic phosphates are initially the most effective buffers. The most important blood buffer is hemoglobin. Deoxygenated hemoglobin readily accepts hydrogen ions to prevent substantial changes in pH, and approximately 10% of CO2 is bound to hemoglobin to form carbaminohemoglobin.

Cellular buffering elevates plasma bicarbonate (HCO3-) only slightly and causes plasma HCO3- to increase 1 mEq/L for every 10-mm Hg increase in PaCO2.

Renal compensation for sustained hypercapnia begins in 6-12 hours, but 3-5 days pass before maximal compensation occurs. The kidneys increase excretion of hydrogen ions (predominantly in the form of ammonium [NH4+]) and chloride while retaining HCO3- and sodium (Na+). This process increases the plasma HCO3- concentration by approximately 3.5-4 mEq/L for every 10-mm Hg increase in PaCO2. As a result, additional NaHCO3- is available to buffer free hydrogen ions. Because neonates and infants have a relatively large amount of hemoglobin and interstitial fluid for their body weight, their increase in plasma HCO3- concentrations and decrease in plasma hydrogen ion concentrations are greater than those of older children.

Chemoreceptors in the brainstem and in the carotid body rapidly detect changes in PaCO2. CO2 is a potent respiratory stimulant and elevated levels lead to an increase in minute ventilation to excrete increased quantities of CO2 and normalize the pH. However, this effect is attenuated if the CO2 level remains elevated for more than several hours. In general, acute respiratory acidemia causes no change or only a slight increase in extracellular potassium and phosphate levels.

Respiratory effects

When a patient develops a respiratory acidosis while breathing air, the alveolar gas equation predicts that hypoxemia will develop. The alveolar gas equation (Equation 2) states that the alveolar partial pressure of oxygen (PAO2) is equal to the partial pressure of inspired oxygen (PiO2) minus the quantity of alveolar partial pressure of CO2 (PACO2) divided by the respiratory quotient (RQ), as follows:

Equation 2: PAO2 = PiO2 - (PACO2/RQ)

The RQ is the ratio of the volume of CO2 expired to the volume of O2 consumed by an organism (see nutrition effects on RQ below). In steady-state conditions, the human body produces CO2 at a rate of approximately 200 mL/min and consumes O2 at a rate of 250 mL/min; therefore, RQ = 0.8. If RQ is rounded to 1, the equation reduces to the following (Equation 3):

Equation 3: PAO2 = PiO2 - PACO2

The PiO2 is the difference between the barometric pressure (PB) and the partial pressure of water vapor (PH2O) multiplied by the fraction of inspired oxygen (FiO2), as shown below (Equation 4):

Equation 4: PiO2 = FiO2 (PB - PH2O)

If the equation is rearranged, PACO2 is ultimately dependent on the level of inspired O2 (Equation 5):

Equation 5: PACO2 = FiO2 (PB - PH2O) - PAO2

Because PB at sea level is 760 mm Hg and PH2O in the atmosphere is 47 mm Hg, when a person is breathing air (FiO2 = 0.21), the sum of PACO2 and PAO2 adds up to approximately 150 mm Hg, as follows (Equations 6 and 7):

Equation 6: PAO2 = 0.21 (760 mm Hg - 47 mm Hg) - PACO2

Equation 7: PAO2 + PACO2 = 149.7 mm Hg

In the acute setting, PaCO2 values higher than 80-90 mm Hg while the patient is breathing air are life threatening because of the associated hypoxemia. When the PaCO2 exceeds 100 mm Hg, an iatrogenic or an acute on chronic condition is present. Hypoventilation can lead to clinically significant hypercarbia without hypoxemia only if a patient is breathing supplemental oxygen.

Consider the case of a child in the pediatric ICU who is breathing supplemental oxygen given by a mask (FiO2 = 0.80). The child has partial airway obstruction or central hypoventilation secondary to narcotic administration. Supplemental oxygen allows for an increased PaCO2 given the principle of the alveolar gas equation without arterial desaturation. The profound acidemia associated with the hypercapnia can lead to bradycardia, the first sign of the problem. Some have used the term supercarbia to describe when the PaCO2 is greater than 150 mm Hg. In this case, PAO2 = [0.80 (760 mm Hg - 47 mm Hg)] - 150 mm Hg = 420 mm Hg.

Hypercapnia is associated with increased pulmonary vascular resistance. However, the absolute CO2 level does not have the greatest effect on pulmonary vascular tone; rather, decreased serum pH most likely mediates the effect. When hypercapnia is combined with acidemia and hypoxemia, resultant pulmonary vasoconstriction can be severe and life threatening.

Cardiovascular effects

Acute respiratory acidosis increases epinephrine and norepinephrine release. Several studies have shown that acute moderate hypercapnia produces a hyperdynamic state defined by tachycardia, high cardiac output, and reduced systemic vascular resistance. In experimental models, cardiac contractility decreases with acute respiratory acidosis. Some have proposed that the rapid development of intracellular acidosis interferes with the interaction between calcium and myofilaments. This adverse effect of acute moderate hypercapnia on myocardial contractility has not been seen in adult human studies. With severe acidemia at a serum pH of less than 7.20, the catecholamine response is blunted, and this change may contribute to a state of decreased cardiac output.

Supraventricular arrhythmias are increased in the presence of a severe respiratory acidosis, but these problems are most likely caused by concomitant hypoxemia, electrolyte shifts, and increased catecholamines rather than a direct hypercapnia-induced cardiac irritability. Cardiovascular symptoms of respiratory acidosis are often difficult to discern because of the concomitant effects of hypoxemia and metabolic acidosis.

Inhaled CO2 gas can be administered to preoperative neonates with hypoplastic left heart syndrome and low systemic cardiac output associated with high arterial saturations (>85%). PaCO2 is maintained above 40 mm Hg, and the patient is mechanically ventilated, sedated, and paralyzed to prevent a compensatory tachypnea. The inhaled CO2 increases pulmonary vascular resistance, thereby shunting blood flow to the systemic circulation away from the pulmonary system, resulting in improved systemic oxygen delivery and cerebral oxygenation. Experimental evidence also suggests that hypercarbia may have some beneficial effects at assisting the mechanical recovery of hypoxic injured myocytes; however, further human clinical correlation is still needed.

CNS effects

The clinical manifestations of acute hypercapnia are primarily neurologic. Acute elevations of PaCO2 greater than 60 mm Hg cause confusion and headache. PaCO2 more than 70 mm Hg produces a hypercapnic encephalopathy or CO2 narcosis manifesting as drowsiness, depressed consciousness, or coma. However, the neurologic changes associated with hypercarbia are reversible. In one report, children without hypoxemia but with severe respiratory acidosis (lowest pH was 6.76, and highest PaCO2 was 269 mm Hg) did not have long-term adverse neurologic or developmental effects.2

Acute elevations in PaCO2 increase intracranial pressure by increasing cerebral blood flow (CBF) and cerebral blood volume secondary to vasodilatation. With a PaCO2 of 40-80 mm Hg, CBF increases 1-2 mL per 100 g of brain per minute for each 1-mm Hg increase in PaCO2. A PaCO2 of 80 mm Hg or more produced a maximal increase in CBF in anesthetized animals. During sustained hypercapnia, CBF returns to baseline after about 36 hours as brain extracellular pH is corrected.

In acute hypercapnia, CO2 rapidly diffuses across the blood-brain barrier, which leads to accumulation of hydrogen ions in the CSF. This change in pH is rapidly detected by the brainstem, causing rapid compensation (ie, increased elimination of CO2 by the lungs). If the CSF acidosis persists for several hours, CSF HCO3- levels gradually increase to normalize the pH. In general, the response of the cerebral circulation to PaCO2 increases during development from the neonatal period to adulthood.

Frequency

See Background.

Mortality/Morbidity

The effects of respiratory acidosis vary according to the severity, the duration, the underlying disease, and the associated arterial saturation. The most important consideration may be the degree to which hypercarbia or the underlying disease adversely affects arterial oxygenation.

Race

No racial distribution is known.

Age

Respiratory acidosis can occur at any age.



History

The following questions should be assessed:

  • Does the patient have a history of headaches? With chronic hypercapnia, headaches typically occur at nighttime or when the patient awakens in the morning.
  • Does the patient have disturbed sleep patterns? Chronic hypercapnia can disturb sleep patterns, leading to a reversed sleep-wake cycle.
  • Is the patient irritable or anxious or is he or she having trouble concentrating?
  • Does the patient have a possible or known exposure to sedatives (eg, narcotics, benzodiazepines, tricyclic antidepressants)? Is the patient recovering from a procedure in which general anesthesia was used?
  • Does the patient have symptoms of neuromuscular weakness or paralysis?
    • Bulbar dysfunction suggesting myasthenia gravis
    • Proximal or distal weakness suggesting a myopathy or Guillain-Barré syndrome
    • Apnea associated with a traumatic injury suggesting an injury to the cervical spinal cord
  • Does the patient have a long-standing pulmonary disease, such as bronchopulmonary dysplasia, CF, asthma, or emphysema?
  • Does the patient have an acute change in mental status (eg, signs of stroke, postictal state)?
    • Is the change in mental status associated with a fever, which may suggest encephalitis or meningitis?
    • Does the patient have signs of increased intracranial pressure (eg, headaches, visual changes, emesis)?
  • Does the patient have a potential for an anaphylactic reaction?
  • Does the patient have a potential traumatic mechanism leading to brain injury?

Physical

  • Neurologic findings
    • Early signs include anxiety, disorientation, confusion, and lethargy.
    • Somnolence or coma occurs when PaCO2 is greater than 70 mm Hg.
    • Tremor, myoclonus, or asterixis are occasionally seen.
    • Brisk deep tendon reflexes are seen in mild-to-moderate respiratory acidosis.
    • Depressed deep tendon reflexes are seen in severe respiratory acidosis.
    • Papilledema or blurring of the optic disc may be present.
  • Cardiovascular findings
    • Tachycardia
    • Bounding arterial pulses
    • Hypotension (severe respiratory acidosis or acidemia and hypoxemia)
  • Skin findings
    • Warm, flushed, or mottled
    • Diaphoretic
  • Respiratory findings
    • Acute hypercapnia is seen in association with increase work of breathing
    • Tachypnea, dyspnea, or deep labored breaths may be observed.
    • Accessory muscle use and nasal flaring are usually present.
    • With CNS or peripheral nervous system disease, respiratory distress may not be present.
    • Decreased aeration, crackles, wheezes, or other signs of airway disease may be observed.
    • Clubbing is a sign of chronic respiratory disease.

Causes

  • CNS respiratory drive suppression causes include the following:
    • Trauma
    • Infection (eg, encephalitis, meningitis, respiratory syncytial virus)
    • Neoplasm
    • Stroke
    • Hypoxia
    • Toxins, overdose (eg, narcotics, alcohol)
    • Seizures - Postictal state
  • Spinal causes include trauma (C-spine C3-C5, phrenic nerve function).
  • Nerve causes include the following:
    • Spinal muscular atrophy
    • Guillain-Barré syndrome
    • Poliomyelitis
    • Phrenic nerve trauma
  • Neuromuscular junction causes include the following:
    • Myasthenia gravis
    • Botulism
    • Neuromuscular blockade
  • Muscle causes include muscular dystrophies.
  • Airway causes include the following:
    • Loss of CNS control
      • Brain injury
      • Toxin, overdose
    • Trauma
    • Angioedema
    • Tonsillar adenoid hypertrophy
    • Thermal or chemical burn
    • Foreign Body
    • Pharyngeal abscess
    • Epiglottitis
    • Paralyzed vocal cords
    • Congenital lesions
      • Subglottic stenosis
      • Laryngomalacia
      • Craniofacial abnormalities
      • Tracheal rings
      • Vascular slings
    • Laryngotracheobronchitis (croup)
    • Neoplasm, mediastinal mass
    • Bronchiolitis
    • Asthma
  • Acute lung injury causes include the following:
    • Pneumonia
    • Pulmonary edema
    • Lung contusion
    • Bronchiolitis
  • Chronic lung disease causes include the following:
    • Bronchopulmonary dysplasia
    • CF
    • Chronic bronchitis
    • Chronic obstructive pulmonary disease
  • Chest wall restriction and reduced respiratory compliance causes include the following:
    • Flail chest
    • Pneumothorax
    • Pleural effusions
    • Kyphoscoliosis
    • Abdominal distension
  • Increased CO2 production causes include the following:
    • Malignant hyperthermia
    • Extensive burns
    • Overfeeding



Alkalosis, Metabolic
Alveolar Proteinosis
Asphyxiating Thoracic Dystrophy (Jeune Syndrome)
Aspiration Syndromes
Asthma
Atelectasis, Pulmonary
Bronchiectasis
Bronchiolitis
Bronchitis, Acute and Chronic
Bronchopulmonary Dysplasia
Congenital Diaphragmatic Hernia
Congenital Stridor
Croup
Cystic Adenomatoid Malformation
Cystic Fibrosis
Empyema
Goodpasture Syndrome
Hantavirus Pulmonary Syndrome
Head Trauma
Hemosiderosis
Hemothorax
Histoplasmosis
Human Immunodeficiency Virus Infection
Mycoplasma Infections
Near Drowning
Neonatal Resuscitation
Respiratory Distress Syndrome


Lab Studies

  • ABG analysis
    • The ABG is diagnostic of a respiratory acidosis.
    • The serum HCO3- level and pH can be helpful in distinguishing acute hypercapnia from chronic hypercapnia. If the pH is greater than 7.45, elevated PaCO2 may compensate for metabolic alkalosis and not a primary process.
  • Tests for acute respiratory acidosis
    • pH decreases 0.08 for every 10-mm Hg increase in PaCO2.
    • HCO3- increases by 1 mEq/L for every 10-mm Hg increase in PaCO2.
    • If PaCO2 increases acutely to 80 mm Hg, the pH is 7.12 and the HCO3- value is 28 mEq/L.
  • Tests for chronic respiratory acidosis
    • pH decreases 0.03 for every 10-mm Hg increase in PaCO2.
    • HCO3- concentration equals 24 mmol/L ± 4 for every 10-mm Hg increase in PaCO2 greater than 40 mm Hg.
    • For example, if the PaCO2 is 80 mm Hg, the pH is 7.28, and the HCO3- value is 40 mEq/L ± 4.
  • Evaluation of HCO3- resorption
    • The HCO3--resorption process is efficient.
    • If a patient with chronic hypercapnia has a pH of more than 7.20, a superimposed acute on chronic respiratory acidosis or concomitant metabolic acidosis is most likely occurring as well.
  • Toxicology screen for narcotics, benzodiazepines, alcohol, or tricyclic antidepressants if indicated
  • Electrolyte assessment for abnormalities associated with muscle weakness (eg, hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia)

Imaging Studies

  • Chest radiography findings may help in the diagnosis.
  • CT scanning of the chest is indicated if the history and physical findings suggest primary pulmonary disease.
  • CT angiography may be indicated to rule out pulmonary embolus.
  • CT scanning or MRI of the brain is indicated if the history and physical findings suggest signs of an intracranial process.
  • MRI of the spine may be indicated by the history and physical findings.

Other Tests

  • Pulmonary function tests, including spirometry if the child can cooperate
  • Electromyelography (EMG), if indicated to evaluate neuromuscular disease
  • Polysomnography, or sleep study, to evaluate for obstructive or central sleep apnea, if indicated



Medical Care

  • The goals of therapy are to remove the underlying cause and return the PaCO2 level to baseline.
  • If hypoxemia accompanies hypercapnia, oxygen should be administered.
    • Diagnosis and directed therapy need to accompany oxygen administration.
    • In chronic hypercapnia, supplemental oxygen therapy can worsen hypercapnia by reducing the respiratory drive and increasing dead-space ventilation due to a loss of hypoxic pulmonary vasoconstriction.
  • Disease-specific interventions may be needed.
    • Antibiotics for pneumonia
    • Naloxone for narcotic associated hypoventilation
    • Bronchodilators (eg, albuterol) and steroids for asthma
  • Noninvasive positive-pressure ventilation (NPPV) may be needed.
    • NPPV can be delivered continuously or intermittently to increase alveolar ventilation and decrease work of breathing.
    • NPPV is effective in the treatment of chronic respiratory failure in patients with restrictive lung disease (eg, neuromuscular disease or kyphoscoliosis).
    • In patients with chronic obstructive pulmonary disease, early application of NPPV in hypercapnic respiratory failure can decrease the need for invasive mechanical ventilation and decrease their length of stay in the hospital.
    • Advantages include a decreased incidence of nosocomial infections such as sinusitis or pneumonia, increased comfort compared with tracheal intubation, and the ability to maintain verbal communication.
    • Disadvantages include facial skin necrosis, conjunctivitis, or aspiration.
  • Mechanical ventilation may be needed.
    • Mechanical ventilation increases minute ventilation and decreases dead space. This approach is the mainstay of treatment for acute hypercapnia.
    • The decision to start mechanical ventilation when an underlying disease is associated with chronic respiratory acidosis should be well thought out and well informed. Because of limited baseline pulmonary reserve, weaning from ventilatory support and extubation is usually difficult.
    • Various clinical factors determine the proper timing and method of mechanical ventilation, including the etiology of the ventilatory failure and patient factors, such as exhaustion, prognosis, and prospect of improvement with concurrent therapy.
    • Acute hypercapnia can be quickly and safely corrected to a normal PaCO2.
    • In chronic hypercapnia, the goal of mechanical ventilation is near-normal pH with the patient's baseline PaCO2. If the PaCO2 must be normalized, this should be done over 2-3 days to prevent a sudden increase in CSF pH, which can cause seizures.
  • Intratracheal pulmonary ventilation may be needed.3
    • Sometimes, mechanical ventilation is ineffective in reducing hypercapnia because of increased dead space.
    • Intratracheal pulmonary ventilation can help in treating intractable hypercapnia.
    • In this procedure, a catheter is placed down the endotracheal tube to produce a reverse flow up the tube. The dead space gas is flushed out, and rebreathing of CO2 decreases.
  • Permissive hypercapnia might be considered.4
    • In acute lung injury and acute respiratory distress syndrome (ARDS), a strategy of low tidal volume (4-6 mL/kg) allows the PaCO2 to rise to 60-70 mm Hg in order to avoid stretch induced lung injury.
    • In a multicenter randomized trial, mechanical ventilation with a low tidal volume decreased mortality and increased the number of days without ventilator use.5
    • A respiratory acidosis (pH >7.25) is acceptable as long as adequate oxygenation and cardiovascular stability are maintained.
    • Permissive hypercapnia is contraindicated in patients with traumatic brain injury, pulmonary hypertension, or renal disease because elevated PaCO2 levels may worsen their underlying disease.
  • Treatment of a concurrent metabolic acidosis or to buffer the acidemia with a respiratory acidosis can be considered.
    • Tromethamine (THAM) (see Medication)
    • NaHCO3- administration should be used carefully if the patient cannot increase minute ventilation because it increases the amount of CO2 to be excreted. Therefore, NaHCO3- should be administered slowly if it is used.

Surgical Care

Some institutions have successfully used extracorporeal membrane oxygenation (ECMO) to reduce high pCO2 states such as when treating patients with severe asthma.

Diet

  • As described above, the RQ describes the ratio of CO2 produced to the amount of oxygen consumed while making energy; the RQ varies depending on the fuel source substrate. The RQ for carbohydrate is 1.0, the RQ for protein is 0.8, and the RQ for fat is 0.7. For the same amount of substrate burned, carbohydrate produces the greatest amount of CO2, and fat produces the least. Patients on a high carbohydrate diet must be able to accommodate or must be provided higher minute ventilation in order to balance the increased CO2 load or run the risk of developing a respiratory acidosis.
  • If obesity is contributing to obstructive sleep apnea, a weight-reduction and exercise program should be part of the management plan
  • Data have suggested that a specialized enteral formula can be a useful adjunctive therapy in the management of ARDS because it reduces lung inflammation and improving oxygenation.
    • The prototype is a low-carbohydrate, calorically dense formula containing eicosapentaenoic acid (EPA) from fish oil, gamma-linolenic acid (GLA) from borage oil, and elevated levels of antioxidants.
    • One commercially available formula is Oxepa (Abbott Laboratories; Abbott Park, IL).



Drug Category: Alkalinizing agents

Mechanical ventilation is the mainstay of therapy for respiratory failure associated with hypercapnia until the precipitating disease state can be reversed. In certain cases, THAM may be helpful.

Drug NameTromethamine (THAM)
DescriptionAlso known as tris[hydroxymethyl]-aminomethane. Combines with hydrogen ions to form HCO3- buffer. Used to prevent and correct systemic or respiratory acidosis. Biologically inert weak base that can buffer excess CO2. Used to correct acute respiratory acidosis, as follows: R-NH2 + CO2 + H2O = R-NH3 + HCO3
At 37°C, pKa is 7.8; therefore, more effective buffer than NaHCO3- in physiologic blood pH range. Not protein bound and distributed primarily in extracellular space. When protonated, excreted by kidneys and acts as osmotic diuretic. Most appropriately administered as short-term infusion during therapeutic window to correct acute respiratory acidosis.
Adult DoseEstimate IV loading dose by the following equation: Volume (mL) of 0.3-M solution = lean body weight (kg) X base deficit (mEq/L) X 1.1
Typical adult dose is about 500 mL (150 mEq) of 0.3-M solution; may use up to 1000 mL in severe situations; titrate to serum pH (some authors practice using half the calculated replacement dose and consider further replacement based on results); 1 mMol = 3.3 mL of 0.3-M solution
Pediatric DoseEstimate IV loading dose by the following equation: Volume (mL) of 0.3-M solution = lean body weight (kg) X base deficit (mEq/L) X 1.1
Do not exceed 40 mL/kg/d IV; infusion rate not to exceed 3-16 mL/kg/h; titrate to serum pH
ContraindicationsDocumented hypersensitivity; anuria; uremia
InteractionsNone reported
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsMay induce respiratory depression and hypoglycemia (require ventilatory assistance and glucose administration); reduce dose in renal impairment; monitor serum and urine pH



Further Inpatient Care

  • Patients with acute respiratory acidosis require admission to the ICU for close monitoring and possible advanced airway management with mechanical respiratory support.
  • Avoid use of narcotics, sedatives, or other respiratory depressants when the patient is breathing spontaneously.
  • Correct electrolyte abnormalities associated with muscle weakness, such as hypophosphatemia, hypokalemia, hypomagnesemia, and hypocalcemia.
  • Maximize nutrition, but avoid overfeeding and high carbohydrate content because these can increase CO2 production.
  • If a metabolic alkalosis develops during diuretic therapy, correct it by replacing chloride and, if needed, careful replacement of potassium.

Further Outpatient Care

  • For chronic respiratory acidosis, frequent follow-up with pulmonary function testing is necessary to provide a reference baseline and to monitor for changes during acute illness.
  • Noninvasive positive-pressure ventilation is an effective home therapy for chronic respiratory failure caused by obstructive sleep apnea, obesity hypoventilation syndrome, or neuromuscular disease. Therapy can be continuous, intermittent with certain activities, or nocturnal.
  • Home nursing can provide additional care.

Complications

  • Respiratory acidosis may precede acute respiratory failure and possible cardiovascular failure.
  • Convulsions may result if PaCO2 levels are restored too quickly in patients with chronic hypercapnia.
  • Posthypercapnic alkalosis can occur in patients with chronic hypercapnia if PaCO2 is rapidly reduced with mechanical ventilation.
    • The kidneys have a relatively slow mechanism to correct the HCO3- excess.
    • The metabolic alkalosis can be treated by replacing chloride, potassium, or by increasing renal HCO3- excretion with acetazolamide. Care must be taken not to correct a compensating metabolic alkalosis with out addressing the underlying respiratory acidosis.
  • If tracheal intubation is required in a spontaneously breathing person with high minute ventilation, care must be taken to maintain that level of minute ventilation to avoid a sudden increase in PaCO2 that could contribute to hemodynamic instability, CNS injury, or cardiopulmonary arrest.
  • Tracheal intubation may lead to upper-airway edema and difficult extubation, especially in chronically ill patients with limited baseline pulmonary reserve.

Prognosis

  • Hypercapnic neurologic changes are reversible with no residual effect.
  • The prognosis depends on the underlying etiology
    • Respiratory acidosis can be an acute and transient event with no long-term sequelae if it is not associated with hypoxemia (eg, seizure and treatment-associated hypoventilation).
    • Respiratory acidosis may be associated with a chronic disease that has associated morbidity (eg, asthma or Duchenne muscular dystrophy).
    • Respiratory acidosis may be the sign of an irreversible progressive disease that leads to death (eg, idiopathic pulmonary hypertension).



Medical/Legal Pitfalls

  • Failure to aggressively manage acute respiratory acidosis with assisted ventilation can lead to an otherwise avoidable respiratory and/or cardiovascular arrest.
  • Use of sedative medications in a nonintubated patient can worsen mild respiratory acidosis, leading to unrecognized CO2 narcosis.
  • Primary respiratory acidosis must be distinguished from secondary hypercapnia due to metabolic alkalosis.
  • Failure to consider a mixed acidosis can lead to missed therapies and diagnosis. Always critically analyze acid-base values by assessing the pH, PaCO2, and HCO3- measurement.



  1. Epstein SK, Singh N. Respiratory acidosis. Respir Care. Apr 2001;46(4):366-83. [Medline].
  2. Goldstein B, Shannon DC, Todres ID. Supercarbia in children: clinical course and outcome. Crit Care Med. Feb 1990;18(2):166-8. [Medline].
  3. Makhoul IR, Bar-Joseph G, Blazer S, et al. Intratracheal pulmonary ventilation in premature infants and children with intractable hypercapnia. ASAIO J. Jan-Feb 1998;44(1):82-8. [Medline].
  4. Laffey JG, O'Croinin D, McLoughlin P, Kavanagh BP. Permissive hypercapnia--role in protective lung ventilatory strategies. Intensive Care Med. Mar 2004;30(3):347-56. [Medline].
  5. ARDS Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342:1301-8. [Medline].
  6. Annane D, Orlikowski D, Chevret S, Chevrolet JC, Raphael JC. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane Database Syst Rev. 2007;(4):CD001941. [Medline].
  7. Brian JE. Carbon dioxide and the cerebral circulation. Anesthesiology. May 1998;88(5):1365-86. [Medline].
  8. Halpern P, Raskin Y, Sorkine P, Oganezov A. Exposure to extremely high concentrations of carbon dioxide: a clinical description of a mass casualty incident. Ann Emerg Med. Feb 2004;43(2):196-9. [Medline].
  9. Kiely DG, Cargill RI, Lipworth BJ. Effects of hypercapnia on hemodynamic, inotropic, lusitropic, and electrophysiologic indices in humans. Chest. May 1996;109(5):1215-21. [Medline].
  10. Low JM, Gin T, Lee TW, Fung K. Effect of respiratory acidosis and alkalosis on plasma catecholamine concentrations in anaesthetized man. Clin Sci (Lond). Jan 1993;84(1):69-72. [Medline].
  11. Mas A, Saura P, Joseph D, et al. Effect of acute moderate changes in PaCO2 on global hemodynamics and gastric perfusion. Crit Care Med. Feb 2000;28(2):360-5. [Medline].
  12. Mazzeo AT, Spada A, Pratico C, et al. Hypercapnia: what is the limit in paediatric patients? A case of near-fatal asthma successfully treated by multipharmacological approach. Paediatr Anaesth. Jul 2004;14(7):596-603. [Medline].
  13. Thome UH, Carlo WA. Permissive hypercapnia. Semin Neonatol. Oct 2002;7(5):409-19. [Medline].
  14. Vavilala MS, Lee LA, Lam AM. Cerebral blood flow and vascular physiology. Anesthesiol Clin North America. Jun 2002;20(2):247-64. [Medline].

Acidosis, Respiratory excerpt

Article Last Updated: Jan 9, 2008